[Wobenzym in the combined pathogenetic therapy of chronic urethrogenic prostatitis].
The paper addresses the issues of pathogenetic therapy of uretrogenous prostatitis, its key features being as follows: 1) association with pancreatic pathology; 2) the presence of noninfectious agent; 3) autoimmune character. The proposed treatment scheme includes wobenzyme, a polyenzymic drug preparation, capable of exerting positive effects in the treatment of the pathology in question, which fact bears relation to intimate mechanisms of evolution of chronic urethrogenous prostatitis.
Martynenko
A V
AV
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000900:Anti-Bacterial Agents; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D003131:Combined Modality Therapy; D004338:Drug Combinations; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D006801:Humans; D006867:Hydrolases / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011472:Prostatitis / Q000188:drug therapy* / Q000209:etiology; D012431:Rutin / Q000627:therapeutic use*; D014522:Urethral Diseases / Q000150:complications*
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D012431:Rutin; C023295:Wobenzym; D006867:Hydrolases
Vobénzim v kompleksnoĭ patogeneticheskoĭ terapii khronicheskogo uretrogennogo prostatita.